Soleno Therapeutics Announces Oral Presentation Featuring DCCR Extended-Release Tablets In Prader-Willi Syndrome At ENDO 2024
Portfolio Pulse from Benzinga Newsdesk
Soleno Therapeutics (NASDAQ:SLNO) will present data on its DCCR extended-release tablets for Prader-Willi Syndrome at the ENDO 2024 conference.
May 22, 2024 | 8:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Soleno Therapeutics will present data on its DCCR extended-release tablets for Prader-Willi Syndrome at the ENDO 2024 conference. This could generate positive attention and potential investor interest.
The presentation at a major conference like ENDO 2024 can increase visibility and credibility for Soleno's DCCR tablets, potentially attracting investor interest and positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100